Skip to main content

Advertisement

Table 2 Survival characteristics for different TP53 risk groups sub-stratified with CAGP model

From: Centrosome associated genes pattern for risk sub-stratification in multiple myeloma

Stratification group N HR (95 % CI) Survival median (months) 3-years outcome (%) p value (log-rank)
Overall survival
 Low risk CAGP 66   38.8 53.8 <0.00799
 High risk CAGP 84 1.8 (1.16; 2.80) 22.1 25.1
 TP53− 110   25.1 35.6 <0.00281
 TP53+ 14 2.5 (1.35; 4.73) 12.8 12.2
 TP53−/low risk CAGP 47   38.8 61.1 <0.00099
 TP53−/high Risk CAGP 63 2.5 (1.41; 4.30) 22.2 20.1
 TP53+/low Risk CAGP 7   12.8 0 <0.3621
 TP53+/high risk CAGP 7 0.5 (0.14; 2.05) 16.7 21.4
Time to progression
 Low risk CAGP 66   13.6 11.5 <0.1939
 High risk CAGP 84 1.3 (0.88; 1.88) 13.0 8.7
 TP53− 110   13.9 11.6 <0.01378
 TP53+ 14 2.1 (1.15; 3.79) 8.7 0
 TP53−/low risk CAGP 47   16.4 15.3 <0.08914
 TP53−/high risk CAGP 63 1.5 (0.94; 2.34) 13.2 8.0
 TP53+/low risk CAGP 7   7.6 0 <0.676
 TP53+/high risk CAGP 7 0.8 (0.23; 2.61) 9.9 0
Progression free survival
 Low risk CAGP 66   12.6 10.8 <0.06232
 High risk CAGP 84 1.4 (0.98; 2.03) 10.2 5.6
 TP53− 110   13.2 8.8 <0.04351
 TP53+ 14 1.8 (1.01; 3.29) 8.7 0
 TP53−/low risk CAGP 47   15.2 14.1 <0.02102
 TP53−/high risk CAGP 63 1.7 (1.07; 2.55) 11.3 4.6
 TP53+/low risk CAGP 7   7.6 0 <0.676
 TP53+/high risk CAGP 7 0.8 (0.23; 2.61) 9.9 0
  1. Low risk CAGP” group includes patients with “Low expressed” centrosome associated gene pattern. “High risk CAGP” group includes patients with united “High and medium expressed” centrosome associated gene pattern. “TP53+” group includes patients with deletion 17p13; “TP53−” group includes patients without deletion 17p13 (positivity cut-off >20 %)